Next Phase Newsletter

The investment firm is a philanthropic venture firm established by a family office to accelerate the development of promising technologies for the diagnosis and treatment of cardiovascular and neurovascular disease through targeted investments. The US-based firm makes 4-5 investments each year of approximately $1 million into privately-held companies worldwide at both the seed and early venture stages. The firm operates under an evergreen structure and has made 43 investments to date.

While the firm is focused on cardiovascular, neurovascular and metabolic diseases (e.g., diabetes, dyslipidemia and obesity), the firm invests across all technology sectors including biotech, medtech, diagnostics, and regenerative medicine. The firm looks to invest in companies where its investment will help move the company to a value inflection point necessary for the next and larger financing round.

The firm invests in technologies that have the potential for a clear impact on patient therapy and/or standard of care, an adequate level of IP protection, well-defined use of proceeds with quantifiable and achievable milestones, and a clear understanding of the next round of fundraising needs including size and likely sources.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm operates from many offices across the globe and has invested in hundreds of companies in a wide variety of sectors. Recently, the firm has been expanding their portfolio in the life science/healthcare sector, and is actively seeking early-stage opportunities. With over $1B AUM, the firm will typically invest up to $3M as an initial check, with a significant portion of their capital dedicated  to follow-on investments. The firm is open to global opportunities, with a focus on USA, Europe, and Asia.

The firm is interested in therapeutics, diagnostics, digital health, and life science tools. The firm’s interest areas also include industrial biotechnology, synthetic biology, and robotics. While the firm does not completely rule out medical device opportunities, they are not a priority for the firm. Within therapeutics, the firm will consider both single assets and platform technologies. In general, the firm is stage and indication agnostic.

The firm has no specific company or management team requirements and is open to working with all types of management teams. The firm can act as a lead, co-lead, or co-investor, and provides operational support for their portfolio companies to help them scale.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science specialist venture fund manager headquartered in Western Europe generally invests in preclinical to clinical-stage life science companies, primarily in the field of therapeutic drug development with products addressing high unmet medical need and complementing pharma pipelines. The firm deploys its capital with a geographic focus on Europe (~2/3 of investments) and North America (~1/3 of investments). Currently, the firm invests out of two new funds: one fund closed in 2021 is focusing on preclinical to early clinical-stage assets; and another fund closed in 2020 is focusing on clinical-stage assets, cross-over/IPO rounds, PIPE investments, etc. The typical investment per round is €15-25m for both funds.

The firm invests in preclinical to clinical-stage life science companies, primarily in the field of therapeutic drug development with products addressing high unmet medical need and complementing Pharma’s pipelines.

The firm seeks a company with a strong and experienced management team and/or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment management firm based in China manages multiple funds and is engaged in equity investment, asset management, merger and acquisition across several industries including healthcare. The firm’s healthcare portfolio includes leading pharmaceutical companies in China. The size of investment varies depending on the deal, but the firm is investing from a 1 billion RMB fund for healthcare. The firm is currently seeking equity investment and licensing opportunities in China and the US. The firm is looking for companies with a China angle and has experience helping companies obtain CFDA approval.

Within healthcare, the firm is interested in medical devices, IVD, medical equipment, home-care products, and other healthcare-related technologies. The firm considers products that have at least completed prototype. The firm prefers products that have already obtained FDA clearance or approval, but it is happy to work with companies who are ~1 year away from FDA approval as well. In terms of indication areas, the firm is interested in diseases with large market potential in China, including oncology, reproductive health, cardiovascular diseases, and diabetes and metabolic disorders.

The firm seeks to work with experienced teams with strong sector knowledge. The firm is looking for products with a China angle and may request distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused venture capital firm has offices in USA and China. The firm manages both USD and RMB denominated funds and generally seeks to make equity investments into emerging life science companies in seed and venture stages; however, the fund also considers commercial-stage companies, depending on the opportunity. The investment size of the USD fund ranges from $5 – $25 million. For the RMB fund, typical investment size is RMB 30- RMB150 million. The firm currently focuses on China-based companies or overseas businesses with a China angle.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics, Biotech R&D Services, Medical Technology and Healthcare IT. The firm is agnostic to disease indications but is most interested in areas with large market potential, including Diabetes, Cardiovascular, Musculoskeletal System and Connective Tissue, Diseases of the Eye and Oncology. Rare diseases are generally less of interest. The firm is open to invest in both small molecules and biologics, and it looks for all classes of devices. The funds are most interested in companies in preclinical and early-clinical stage, but they are open to companies in late-clinical and growth stage, on a case-by-case basis.

The firm will only invest in private companies. The firm is looking to be an active investor, sometimes taking a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The Fund is a subsidiary of a Pharmaceutical Group, a diversified enterprise group headquartered in China with an annual revenue of ~$600M. The Fund has a USA office in Los Angeles, CA. The parent company incorporates the following ecosystems:

(1) Commercialization Platform Ecosystem: The company operates as a commercialization platform in China for global high-quality pharmaceuticals, health brand operations, wholesale distribution, and retail. The firm has a strong marketing network of over 12,000 large and medium-sized hospitals and 300,000 pharmacies, as well as hundreds of upstream enterprises.

(2) Health Finance: The Fund seeks to incubate innovative businesses in the healthcare industry by providing financial capital and industrial support. The firm has invested in smart healthcare, diagnostics, R&D and manufacturing, etc.

The firm is open to global opportunities that have strong China market potential.

The Fund is currently focused on late stage investment opportunities and partnerships; in the life sciences, the firm is most interested in oncology/immuno-oncology therapeutics, diagnostics and tools, and technologies that integrate AI. Within therapeutics, the firm will consider various modalities including cell & gene therapy. The firm does not completely rule out early-stage opportunities, as the firm may consider investing in more early stages in the near future and are very keen to exploring novel technologies across all stages of development.

The Fund does not have very specific company or management team requirements, but does require that they demonstrate strong market potential in China, as that is where the firm’s primary business activities are based in. The firm is able to leverage their resources to provide companies with regulatory and commercialization support. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The Fund, founded in 2009, is a venture capital firm based in China. The firm makes early-growth stage investments, preferably from angel/seed to B), but will consider series C. The firm typically invests USD 1-30 million per company. The firm prefers to invest in companies based in China, but is open to outstanding Chinese-led companies based in the US and Canada. The firm is actively seeking new investment opportunities.

In the life sciences, the firm currently considers therapeutics and diagnostics in bone/joint diseases, renal diseases, autoimmune deasese, cancer, and fibrosis. The firm is especially interested in immunotherapy, gene editing, and stem cell therapy that have preclinical data. Clinical data is desired, but not required.

The firm typically seeks Chinese-led teams with strong technical expertise and industry experience. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.